GERN
GERON CORP
NASDAQ · Healthcare · Biotechnology · US
$1.20
+2.56%Year over year
Reported trailing growth
- Revenue
- +24.4%
- EBITDA
- +29.2%
- EBIT
- +51.7%
- EPS
- +25.4%
- Free cash flow
- +35.6%
- Operating cash flow
- +35.8%
Forward estimates
Based on analyst estimates
- Revenue
- +55.0%
- EBITDA
- +313.3%
- EPS
- +148.1%
Three-year CAGR
- Revenue
- +575.7%
- EBITDA
- +66.5%
- EBIT
- +69.0%
- Net income
- +50.9%
- EPS
- +51.9%
- Free cash flow
- +49.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026